tomivosertib + paclitaxel
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer
Trial Timeline
Aug 25, 2020 → Jul 4, 2022
NCT ID
NCT04261218About tomivosertib + paclitaxel
tomivosertib + paclitaxel is a phase 1 stage product being developed by eFFECTOR Therapeutics for Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04261218. Target conditions include Breast Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04261218 | Phase 1 | Completed |
Competing Products
20 competing products in Breast Cancer